# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study.
Larger-than-expected drop in June CPI inflation rate fuels expectations for Fed rate cuts. PPI report will be crucial in evalua...
A lower-than-expected inflation report for June caused wild market reactions, leading to a surge in traders’ expectations of Fe...
S&P 500 and Nasdaq 100 indices surged to new all-time highs on Friday, driven primarily by a rally in Magnificent Seven sto...
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for...
Futures on U.S. equity indices rise slightly after Fed's favorite inflation gauge falls to lowest level since Nov 2021, inc...
Gold Fields shares have trailed the GDX by approximately 23%, despite favorable gold prices owing to recent operational volatil...
As the price of gold continues to soar, prominent economists Mohamed A. El-Erian and Peter Schiff are emphasizing the ongoing s...